Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product ca… Read more
Eagle Pharmaceuticals Inc (EGRX) - Total Liabilities
Latest total liabilities as of June 2023: $152.78 Million USD
Based on the latest financial reports, Eagle Pharmaceuticals Inc (EGRX) has total liabilities worth $152.78 Million USD as of June 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eagle Pharmaceuticals Inc - Total Liabilities Trend (2012–2022)
This chart illustrates how Eagle Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Eagle Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eagle Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coliseum Acquisition Corp. Class A Ordinary Share
NASDAQ:MITA
|
USA | $5.25 Million |
|
Bitmine Immersion Technologies Inc
PINK:BMNR
|
USA | $4.65 Million |
|
Compania Introductora de Buenos Aires SA
BA:INTR
|
Argentina | AR$32.45 Billion |
|
ROK Resources Inc.
OTCQB:ROKRF
|
USA | $41.84 Million |
|
Daesung Eltec Co. Ltd
KQ:025440
|
Korea | ₩292.76 Billion |
|
Case Group AB
ST:CASE
|
Sweden | Skr65.31 Million |
|
Verusaturk Girisim Sermayesi
IS:VERTU
|
Turkey | TL10.84 Million |
|
PS International Group Ltd. Ordinary Shares
NASDAQ:PSIG
|
USA | $4.53 Million |
Liability Composition Analysis (2012–2022)
This chart breaks down Eagle Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eagle Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eagle Pharmaceuticals Inc (2012–2022)
The table below shows the annual total liabilities of Eagle Pharmaceuticals Inc from 2012 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $172.60 Million | +123.35% |
| 2021-12-31 | $77.28 Million | +15.03% |
| 2020-12-31 | $67.18 Million | -10.88% |
| 2019-12-31 | $75.38 Million | -3.16% |
| 2018-12-31 | $77.84 Million | -14.38% |
| 2017-12-31 | $90.92 Million | +45.83% |
| 2016-12-31 | $62.34 Million | +81.96% |
| 2015-12-31 | $34.26 Million | +68.65% |
| 2014-12-31 | $20.32 Million | +26.58% |
| 2013-12-31 | $16.05 Million | -25.48% |
| 2012-12-31 | $21.54 Million | -- |